• fbd@amritahospitals.org
  • 0129 - 2851234

Dr. Prashant Mehta

Senior Consultant

Department

Medical Oncology / Hematoncology / BMT

Qualification

MBBS -Maulana Azad Medical College (MAMC, Delhi)-2006 MD - Medicine (Lady Hardinge Medical College, Delhi)-2010 DM - Medical Oncology , All India Institute of Medical Sciences (AIIMS, Delhi)-2014 Visiting Physician fellowship in BMT/Cellular therapy- Fred Hutchinson Cancer research Center, Seattle USA -2016

Dr. Prashant Mehta, a noted Medical Oncologist and a Bone marrow transplant physician, believes that the goal of treatment apart from cure and disease control is happiness and quality of life. He believes in transparency between patient, family, and treating Doctor pertaining to all aspects of treatment. He is leading the cellular therapy program at Amrita, as well as, working on making CAR- T cell therapies accessible in India by working in close collaboration with researchers and scientists in India as well as outside. He is skilled in immunotherapy and precision oncology and employs these effectively in suitable scenarios. He obtained his DM fellowship in medical oncology and BMT from AIIMS, New Delhi. He is also an alumnus of the prestigious Maulana Azad Medical College, New Delhi. His primary areas of focus are Acute Leukemia and Lymphoma in children and adults, Bone marrow transplantation, including haploidentical transplants and reduced toxicity transplantation.
  • MBBS -Maulana Azad Medical College (MAMC, Delhi)-2006
  • MD - Medicine (Lady Hardinge Medical College, Delhi)-2010
  • DM - Medical Oncology , All India Institute of Medical Sciences (AIIMS, Delhi)-2014
  • Visiting Physician fellowship in BMT/Cellular therapy- Fred Hutchinson Cancer research Center, Seattle USA -2016
  • Acute Leukemia and Lymphoma in children and adults
  • Bone marrow transplantation
  • Meghna Krishna Baweja award
  • Prof GS Bhattacharya award 2021
  • Founder Member of Science and Cost Cancer Consortium
  • Artemis hospital , Gurugram
  • 2015- Associate Consultant -Deptt of Medical Oncology and BMT
  • 2016- Consultant - Deptt of Medical Oncology and BMT
  • Asian Institute of Medical Sciences, Faridabad
  • 2016-2020- Consultant and Unit Head- Deptt of Medical Oncology, Hemat-oncology and BMT Clinical Lead/ Program Director - Leukemia and Bone marrow transplantation services
  • 2020-2022- Senior Consultant and Unit Head - Deptt of Medical Oncology, Hemat-oncology and BMT Clinical Lead/Program Director - Leukemia and Bone marrow transplantation services
  1. Mehta P, Arora R. Clofarabine-based conditioning for T-cell replete haploidentical hematopoietic stem cell transplant for relapsed/refractory acute leukemia using peripheral blood stem cell grafts and post-transplantation cyclophosphamide. Cancer Res Stat Treat [serial online] 2020 [cited 2022 Jul 28];3:614-7. Available from: https://www.crstonline.com/text.asp?2020/3/3/614/295513
  2. Mehta P et al. Utility of Serial Measurement of Serum C-Reactive Protein and Procalcitonin in Patients Undergoing HSCT https://tct.confex.com/tct/2020/meetingapp.cgi/Paper/14986
  3. Prashant Mehta, Rahul Arora, Swati Pabbi. Feasibility of Cyclosporine a Instead of Tacrolimus after Haploidentical Transplantation Using PBSC Grafts with Post-Transplant Cyclophosphamide for Hematological MalignanciesBiology of Blood and Marrow Transplantation,Volume 26, Issue 3, Supplement,2020,Page S279, https://doi.org/10.1016/j.bbmt.2019.12.545.
  4. Mehta P, Bothra SJ. PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review. Adv Genet. 2021;108:35-80. doi: 10.1016/bs.adgen.2021.08.002. Epub 2021 Oct 23. PMID: 34844716.
  5. Mehta P et al."Oncotype DX: Where Does It Stand in India?." Journal of Global Oncology, 5, pp. 1–2 © 2019 by American Society of Clinical Oncology
  6. Patel A, Mehta P, Tannock IF, Srivastava P, et al. Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets. JCO Glob Oncol. 2020;6:382-386. doi:10.1200/JGO.19.00341
  7. Bahl A, Talwar V, Sirohi B, Mehta P, Arya D, Shrivastava G, Dahiya A and Pavithran K (2020) Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC). Front. Oncol. 10:964. doi: 10.3389/fonc.2020.00964
  8. Bhethanabhotla S, Pramanik R, Srivastava P, Mehta P, Patel A, Biswas B, et al. Colorectal cancer chemotherapy during COVID-19 pandemic. Indian J Med Paediatr Oncol
  9. Biswas B, Ganguly S, Dabkara D, Ghosh J, Srivastava P, Mehta P, Patel A, Bhethanabhotla S, Batra A, Pramanik R, Gupta VG, Das CK, Mahindru S. How we treat lung cancer during SARS-Cov-2 (COVID-19) pandemic in India?. Indian J Med Paediatr Oncol 2020;41:149-52
  10. Mahindru S, Das CK, Patel A, Mehta P, Biswas B, Batra A, Bandhopadhyay A. Cancer surgery in challenging time of COVID-19 pandemic – A pragmatic approach. Indian J Med Paediatr Oncol 2020;41:144-8
  11. Ghosh J, Ganguly S, Biswas B, Dabkara D, Srivastava P, Patel A, Batra A, Mehta P. Systemic treatment of gastroesophageal cancer during SARS-CoV2. Indian J Med Paediatr Oncol 2020;41:141-3
  12. Pramanik R, Srivastava P, Sharma A, Mehta P, Patel A, Bhethanbhotla S, Biswas B, Batra A, Gupta VG, Das CK, Mahendru S. Management of head-and-neck cancer during COVID-19 crisis: A medical oncology perspective. Indian J Med Paediatr Oncol 2020;41:153-5
  13. Patel A, Batra A, Mehta P, Sharma A, Sirohi B, Biswas B, Gangulay S, Gupta VG. Gallbladder cancer: Adjuvant and palliative treatment during Covid-19 pandemic in India. Indian J Med Paediatr Oncol 2020;41:132-4
  14. Batra A, Mehta P, Patel A, Bhethanabhotla S, Biswas B, Pramanik R, Das CK. Breast cancer treatment during the COVID-19 pandemic. Indian J Med Paediatr Oncol 2020;41:135-7
  15. Das CK, Mahindru S, Patel A, Batra A, Biswas B, Mehta P, Pramanik R, Bhethanabhotla S, Gupta VG. How I treat epithelial ovarian cancer during COVID-19 pandemic. Indian J Med Paediatr Oncol 2020;41:138-40
  16. Srivastava P, Tilak T V, Patel A, Das CK, Biswas B, Mahindru S, Pramanik R, Ghosh J, Mehta P. Advisory for cancer patients during the COVIDpandemic. Cancer Res Stat Treat 2020;3, Suppl S1:145-8
  17. Das CK, Mehta P et al. Anti-Her2neu directed therapy in advanced gall bladder cancer: A prospective, multicenter experience from India.https://meetinglibrary.asco.org/record/186667/abstract
  18. Mehta P, Parikh P, Aggarwal S, Batra A, Patel A, Kulkarni P, et al. Has India met this enemy before? From an eternal optimist’s perspective: SARS-CoV-2. Indian J Med Sci 2020;72(1):8-12.
  19. Parikh PM, Mehta P, Krishna Mohan MVT, Bhattacharya G S, Govind Babu K. “Serious Adverse Events” faced by clinical trials: Impact of the COVID-19 pandemic. Indian J Med Paediatr Oncol 2020;41:127-31
  20. Mehta P, Bhajoni PS, Mehta SP. Fighting cancer through an informed society. J Soc Health Diabetes 2016 [cited 2017 Jan 31];4:57-66
  21. Mehta P, Raina V, Kumar L, et al. Nasal NK-T cell lymphoma: 10-year experience of a single institute in India. ; J Clin Oncol 32, 2014 (suppl; abstr e19536)
  22. Ajay Gogia, Prashant Mehta, Raja Pramanik, Rajive Kumar. Isolated Breast Relapse Mimicking Breast Cancer in Elderly Patient with Acute Lymphoblastic Leukemia;Turk J Hematol 2014;31:203-204
  23. Ajay Gogia, Prashant Mehta,Ritu Gupta et al.Chronic lymphocytic leukemia with massive ascites: An unusual presenting manifestation; South Asian J Cancer. 2014 Oct- Dec; 3(4): 235–236.
  24. Gogia A, Raina V, Kumar L, Sharma A, Mehta P, Sharma MC. Diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia: A single center experience. South Asian J Cancer 2014;3:186
  25. Gogia A, Mehta P, et al.Cryptococcal meningitis in chronic lymphocytic leukemia; Indian J Cancer. 2013 Oct-Dec;50(4):301
  26. Ankur Bahl, Prashant Mehta, and Vinod Raina. Severe Eosinophilia in Metastatic Carcinoma Breast: A Rare Paraneoplastic Phenomenon; Eur J clin med onc ,sept 2012
  27. Mehta P, Rohtagi A, Sharma S K. et al. A case report of Rheumatoid Arthritis presenting with Right Heart Failure due to Pulmonary Artery Hypertension; Max Med J; vol 4,1, 2009, 7-9.
  28. Mehta P, Rohtagi A, Sharma S K. et al. A case of Mixed connective Tissue Disease presenting with alopecia Ind. J. Clin Pr, Vol. 19, 9, 2009; 37-39
  29. Mehta P, Raina V, Kumar L, et al. Nasal NK-T cell lymphoma: 10-year experience of a single institute in India. ; under consideration in National medical journal of India
  30. MEHTA, Prashant; BHAJONI, Pranjit Santonu; MEHTA, Swati Pabbi. Response to afatinib, after gefitinib and erlotinib, in a patient with advanced adenocarcinoma of lung with brain metastasis: A case report. International Journal of Molecular and Immuno Oncology, [S.l.], v. 2, n. 1, p. 22-24, jan. 2017.
  31. PARIKH, Purvish M, Mehta P. et al. Oncology Gold Standard™ consensus statement on counseling patients for molecular testing and personalized cancer care. International Journal of Molecular and Immuno Oncology, [S.l.], v. 2, n. 2, p. 47-57, jun. 2017